EGFR and non-small cell lung carcinoma: Thus, given the apparently variable response of TKI-treated cases with uncommon mutants (alone or combined) the exact prognostic and predictive role of these mutations in NSCLC treated with different EGFR-TKIs remains to be further investigated.